BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2337 related articles for article (PubMed ID: 18616789)

  • 1. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
    Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
    Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
    Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
    Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients.
    Mangas C; Hilari JM; Paradelo C; Rex J; Fernández-Figueras MT; Fraile M; Alastrue A; Ferrándiz C
    Ann Surg Oncol; 2006 Jul; 13(7):910-8. PubMed ID: 16788751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients.
    Kammula US; Ghossein R; Bhattacharya S; Coit DG
    J Clin Oncol; 2004 Oct; 22(19):3989-96. PubMed ID: 15459222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.
    Rutkowski P; Nowecki ZI; van Akkooi AC; Kulik J; Wanda M; Siedlecki JA; Eggermont AM; Ruka W
    Ann Surg Oncol; 2010 Dec; 17(12):3314-23. PubMed ID: 20607422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
    Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
    J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
    Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
    Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tyrosinase reverse transcriptase PCR analysis in melanoma sentinel lymph nodes: long-term follow-up analysis.
    González Cao M; Badenas C; Malvehy J; Martí R; Puig-Butille JA; Castel T; Rull R; Vilalta A; Vidal-Sicart S; Palou J; Vilella R; Conill C; Sánchez M; Walker G; Pons F; Puig S
    Clin Exp Dermatol; 2009 Dec; 34(8):863-9. PubMed ID: 19438551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
    Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
    Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.
    Manca G; Romanini A; Pellegrino D; Borsò E; Rondini M; Orlandini C; Zucchi V; Pasqualetti F; Mariani G
    J Nucl Med; 2008 Nov; 49(11):1769-75. PubMed ID: 18927334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
    Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
    Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular staging in stage II and III melanoma patients and its effect on long-term survival.
    Voit C; Kron M; Rademaker J; Schwürzer-Voit M; Sterry W; Weber L; Ozdemir C; Proebstle T; Keilholz U
    J Clin Oncol; 2005 Feb; 23(6):1218-27. PubMed ID: 15718319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes.
    Goydos JS; Patel KN; Shih WJ; Lu SE; Yudd AP; Kempf JS; Bancila E; Germino FJ
    J Am Coll Surg; 2003 Feb; 196(2):196-204; discussion 204-5. PubMed ID: 12595045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients.
    Blaheta HJ; Roeger S; Sotlar K; Schittek B; Breuninger H; Bueltmann B; Garbe C
    Br J Dermatol; 2004 Mar; 150(3):477-83. PubMed ID: 15030330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 117.